Skip to main content

Table 1 Demographic characteristics of all 208 patients

From: Clinical risk factors and predictive score for the non-dipper profile in hypertensive patients: a case-control study

Characteristics

Total

(n = 208)

Dippers

(n = 104)

Non-dippers

(n = 104)

P-value

Age (years)

58.2 + 16.7

53.5 + 16.9

63.0 + 15.0

<  0.001

Male n (%)

77 (37)

44 (42.3)

33 (31.7)

0.114

Body weight (kg)

65.6 + 13.4

67.3 + 14.0

63.9 + 12.6

0.066

BMI (kg/m2)*

24.6 (21.7, 27.5)

24.7 (21.8, 27.6)

24.2 (21.5, 27.2)

0.523

Smoking n (%)

10 (4.8)

10 (9.6)

0 (0)

0.001

Co-morbidities n (%)

 Diabetes mellitus

47 (22.6)

13 (12.5)

34 (32.7)

< 0.001

 Dyslipidemia

122 (58.7)

50 (48.1)

72 (69.2)

0.002

 Obstructive sleep apnea

15 (7.2)

8 (7.7)

7 (6.7)

0.789

 Ischemic stroke

12 (5.8)

2 (1.9)

10 (9.6)

0.017

 Coronary artery disease

10 (4.8)

4 (3.8)

6 (5.8)

0.517

 Heart failure

1 (0.5)

1 (1)

0 (0)

1.000

 Chronic kidney disease

38 (18.3)

13 (12.5)

25 (24)

0.031

Number and type of anti-hypertensive medications n (%)

   

0.497

 1

50 (24)

24 (23.1)

26 (25)

 

 2

39 (18.8)

22 (21.2)

17 (16.3)

 

 3

33 (15.9)

15 (14.4)

18 (17.3)

 

 4

19 (9.1)

6 (5.8)

13 (12.5)

 

 5

6 (2.9)

3 (2.9)

3 (2.9)

 

Diuretics

28 (13.5)

15 (14.4)

13 (12.5)

0.685

CCBs

95 (45.7)

40 (38.5)

55 (52.9)

0.037

ACEIs

34 (16.3)

18 (17.3)

16 (15.4)

0.708

ARBs

66 (31.7)

30 (28.8)

36 (34.6)

0.371

Beta blockers

57 (27.4)

22 (21.2)

35 (33.7)

0.043

Peripheral alpha-1 blockers

27 (13)

11 (10.6)

16 (15.4)

0.302

Central acting alpha-2 agonists

9 (4.3)

4 (3.8)

5 (4.8)

1.000

Direct vasodilators

13 (6.2)

10 (9.6)

3 (2.9)

0.045

Laboratory results

 Hemoglobin (g/L)a

132 (120, 145)

134 (125, 148)

130 (117, 140)

0.006

 Hematocrit (%)

40.6 + 4.8

41.6 + 4.5

39.7 + 4.8

0.005

 RDW (%)a

13.6 (12.8, 14.6)

13.4 (12.7, 14.6)

13.7 (12.9, 14.6)

0.225

 MCV (fl)a

88.5 (82.2, 91.9)

87.8 (80.9, 91.0)

89.1 (84.0, 92.0)

0.162

 NLRa

1.80 (1.33, 2.44)

1.79 (1.29, 2.50)

1.85 (1.42, 2.36)

0.623

 PLRa

123.25 (97.18, 161.71)

128.39 (98.91, 166.90)

120.95 (95.09, 158.13)

0.353

 Fasting plasma glucose (mmol/L)a

5.5 (5.1, 6.3)

5.4 (4.9, 5.9)

5.8 (5.3, 6.4)

< 0.001

 HbA1c (%)a

6.0 (5.6, 6.5)

6.0 (5.7, 6.4)

6.0 (5.6, 6.6)

0.655

 Cholesterol (mmol/L)

4.72 + 0.91

4.84 + 0.89

4.61 + 0.92

0.060

 Triglyceride (mmol/L)a

1.12 (0.88, 1.58)

1.15 (0.92, 1.71)

1.11 (0.87, 1.55)

0.495

 HDL-cholesterol (mmol/L)

1.53 + 0.44

1.51 + 0.47

1.55 + 0.41

0.560

 LDL-cholesterol (mmol/L)

2.61 + 0.84

2.72 + 0.86

2.50 + 0.80

0.054

 Uric acid (mmol/L)

0.35 + 0.10

0.36 + 0.11

0.33 + 0.10

0.128

 Abnormal proteinuria n (%)

55 (26.4)

20 (19.2)

35 (33.7)

0.346

 Serum creatinine (μmol/L)a

76.02 (64.53, 97.24)

76.02 (63.65, 94.59)

76.02 (64.53, 103.43)

0.583

 eGFR (ml/min/1.73 m2)

80.22 + 24.25

84.69 + 22.98

75.75 + 24.76

0.008

  1. BMI body mass index, CCBs calcium channel blockers, ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin II receptor blockers, RDW red blood cell distribution width, MCV mean cell volume, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, HbA1c hemoglobin A1c, HDL high density lipoprotein, LDL low density lipoprotein, eGFR estimated glomerular filtration rate
  2. apresented as median and 25th, 75th percentile